Mangafodipir
From Wikipedia, the free encyclopedia
 |
|
|
Mangafodipir
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | V08 |
| PubChem | |
| Chemical data | |
| Formula | C22H28MnN4O14P2 |
| Mol. mass | 689.362 g/mol |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | 27% (manganese) Negligible (DPDP) |
| Metabolism | ? |
| Half life | 20 minutes (manganese) 50 minutes (DPDP) |
| Excretion | Renal and fecal (manganese) Renal (DPDP) |
| Therapeutic considerations | |
| Pregnancy cat. |
Not to be used |
| Legal status | |
| Routes | Intravenous infusion |
Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified.
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
